Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(IV) fluoride of the grains. The reaction can also be carried out starting from manganese powder in a fluidized bed. Other preparations of MnF include the fluorination of MnF with krypton difluoride, or with F in liquid hydrogen fluoride solution under ultraviolet light. Manganese tetrafluoride has also been prepared (but not isolated) in an acid–base reaction between antimony pentafluoride and KMnF as part of a chemical synthesis of elemental fluorine. Manganese tetrafluoride is in equilibrium with manganese(III) fluoride and elemental fluorine: Decomposition is favoured by increasing temperature, and disfavoured by the presence of fluorine gas, but the exact parameters of the equilibrium